In trading on Friday, shares of Virtus Investment Partners Inc's 7.25% Series D Mandatory Convertible Preferred Stock (VRTSP) were yielding above the 7% mark based on its quarterly dividend (annualized to $7.25), with shares changing hands as low as $102.83 on the day. This compares to an average yield of 5.66% in the "Financial" preferred stock category, according to Preferred Stock Channel. As of last close, VRTSP was trading at a 5.17% premium to its liquidation preference amount, versus the average premium of 3.13% in the "Financial" category. It should be noted that the preferred shares are convertible, with a conversion ratio of $110 and $132.The chart below shows the one year performance of VRTSP shares, versus VRTS: Below is a dividend history chart for VRTSP, showing historical dividend payments on Virtus Investment Partners Inc's 7.25% Series D Mandatory Convertible Preferred Stock: In Friday trading, Virtus Investment Partners Inc's 7.25% Series D Mandatory Convertible Preferred Stock ( VRTSP) is currently down about 2.2% on the day, while the common shares ( VRTS - Get Report) are down about 1.4%.
More from Stocks
HP Slips Lower After Rejecting $32.6 Billion Xerox Takeover; Says Open To Talks
HP shares were indicated lower in pre-market trading Monday after the personal computer maker rejected a potential $32 billion takeover bid from Xerox while noting it was "open to exploring" a potential tie-up with its smaller rival.
Dow Futures Edge Higher, Global Stocks Gain After China Rate Cut, Trade Comments
Wall Street futures edged higher Monday, while global stocks recorded firm gains across the board, as investors extended bets on a near-term U.S.-China trade deal and reacted to a rare rate cut from from Beijing that lifted Asia markets.
PG&E Warns of Potential Major Power Shut Off on Wednesday
Wind storm could trigger a public safety power shutoff for a portion of homes and businesses in the Sierra Foothills, North Valley and North Bay.
Novartis Still a Buy Despite Controversy Over Blockbuster Drug
Despite the issues that have bubbled up related to its breakthrough drug for spinal muscular atrophy, Zolgensma, Novartis "has the newest pipeline with many drugs just beginning to have an impact on the company's bottom line," Cramer told members of his Action Alerts PLUS club for investors during an exclusive video-conference call.
Could Netflix Survive on Just Its Own Original Content?
Netflix says that viewers shell out for original shows like Stranger Things and Orange is the New Black -- but production costs have ballooned roughly 30% since last year, which has many investors spooked.